RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 Bifeprunox: Efficacy with Minimal Metabolic Concerns
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 2
SP 13
OP 13
DO 10.1177/155989770700700206
UL http://mdc.sagepub.com/content/7/2/13.abstract
AB Bifeprunox, a partial dopamine agonist, is being developed as a possible treatment for schizophrenia. The results of a 6-month randomized, double-blind, placebo-controlled study of 497 patients with schizophrenia.